RadNet, Inc.

RadNet, Inc. (RDNT) Market Cap

RadNet, Inc. has a market capitalization of .

No quote data available.

CEO: Howard G. Berger

Sector: Healthcare

Industry: Medical - Diagnostics & Research

IPO Date: 1997-01-03

Website: https://www.radnet.com

RadNet, Inc. (RDNT) - Company Information

Market Cap: -|Sector: Healthcare

Company Profile

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of images in the field of mammography, as well as AI solutions for lung and prostate cancer. As of December 31, 2021, it owned and managed 347 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.

Analyst Sentiment

88%
Strong Buy

From 8 Active Polls

1Y Forecast: $86.00

▲ +0.0% Potential Upside

Consensus Target Metrics

Low Bound

$65

Median

$91

High Bound

$92

Average

$86

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$86.00
▲ +58.26% Upside
Low Target
$65.00
20% Risk
Median Target
$91.00
67% Mid
High Target
$92.00
69% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

Historical valuation matrix unavailable.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 RADNET INC (RDNT) — Investment Overview

🧩 Business Model Overview

RADNET operates in diagnostic imaging across outpatient imaging centers and radiology services (including interpretation/teleradiology workflows). The value chain links (1) acquisition of imaging volumes through physician referrals and payer contracting, (2) delivery of imaging studies through owned/managed facilities and advanced imaging modalities, and (3) interpretation and reporting through radiologist staffing and standardized radiology processes. This creates an integrated operating loop: stable facility capacity supports interpretation volumes, while interpretation scale improves turnaround efficiency and strengthens relationships with referring providers and ordering patterns—helping sustain patient flow and reading volume for continuing studies and follow-on imaging.

💰 Revenue Streams & Monetisation Model

RADNET’s monetisation is primarily derived from:
  • Imaging service revenue generated through technical and professional components (equipment time, facility overhead, and professional interpretation/reporting).
  • Radiology services revenue from professional reading and interpretation contracts, which tend to be structurally more recurring than pure one-off modalities due to ongoing referral and clinical workflow needs.
  • Ancillary contract and management-type revenue tied to operating imaging programs and physician/radiology service delivery (where applicable), with profitability driven by standardized protocols and throughput.
Margin drivers are largely operational: utilization of imaging assets, labor productivity (radiologists, technologists, and administrative staff), payer reimbursement mix, and coding/claims effectiveness. Because imaging delivery involves meaningful fixed costs (equipment, facilities, credentialing, and compliance), operating leverage depends on maintaining volume stability and minimizing downtime.

🧠 Competitive Advantages & Market Positioning

RADNET’s moat is best characterized as a combination of switching costs and credentialing/contracting barriers, supported by scale in workflow and an integrated care-delivery ecosystem.
  • Switching costs (workflow + relationships): Referring providers and health systems often maintain established referral pathways based on turnaround times, report quality, and coordination with clinical workflows. Moving imaging services typically requires re-contracting, operational onboarding, and workflow redesign for ordering, PACS/RIS integration, and radiology reporting standards.
  • Credentialing and compliance barriers: Radiology delivery and facility operations require ongoing credentialing, regulatory compliance, radiation safety practices, and payer-specific contracting. These barriers raise the difficulty for new entrants to scale quickly.
  • Scale-driven throughput and cost discipline: A larger interpretation and facility footprint supports more consistent utilization and standardized processes, which can improve margin stability versus fragmented local competitors.
Competitive benchmarking (industry focus):
  • Envision Healthcare (radiology services platform): Envision competes for professional radiology interpretation programs and hospital/health-system relationships. RADNET’s differentiation leans toward outpatient imaging delivery and integrated interpretation workflows rather than purely hospital-dependent coverage.
  • HCA Healthcare (hospital-owned imaging operations): Hospital systems provide imaging through internal departments, benefiting from internal patient flow. RADNET competes by serving outpatient pathways and physician referral networks that may be less tied to inpatient throughput.
  • Independent imaging groups and regional radiology networks (fragmented local competitors): These players often compete on single-modality offerings or local payer relationships. RADNET’s advantage lies in broader scale and workflow standardization across sites.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, structural drivers supporting addressable growth include:
  • Outpatient imaging shift: Care delivery continues moving toward outpatient settings, where imaging demand is sustained by ambulatory diagnostic pathways and shorter episode-of-care cycles.
  • Chronic disease prevalence: Cardiovascular disease, oncology surveillance, orthopedic degeneration, and other chronic conditions drive repeat imaging over time (follow-on studies create demand durability).
  • Radiology subspecialty needs and coverage models: Increasing complexity in imaging interpretation and reporting supports scale models that can coordinate radiologist coverage and turnaround commitments.
  • Contracting and reimbursement optimization: Effective coding, claims accuracy, and payer contracting discipline can improve net reimbursement versus peers, supporting long-term unit economics.
TAM expansion is less about opening entirely new markets and more about increasing share within existing physician referral territories and expanding facility and interpretation capacity where demand density supports utilization.

⚠ Risk Factors to Monitor

  • Reimbursement pressure: Government and commercial payer reimbursement changes (including policy shifts affecting imaging reimbursement structures) can compress margins.
  • Utilization and volume variability: Imaging services have meaningful fixed cost bases; downturns in referral volumes or shifts in care pathways can reduce operating leverage.
  • Regulatory and compliance exposure: HIPAA privacy requirements, radiation safety standards, billing/coding compliance, and evolving state/federal oversight create ongoing operational risk.
  • Labor and credentialing constraints: Radiologist supply, technologist staffing, and ongoing credentialing requirements can limit throughput and increase cost structure.
  • Technological disruption (including AI in imaging workflows): Automation can improve efficiency but may also alter pricing dynamics or competitive positioning if payer/provider contracts adjust to lower-margin workflow economics.
  • Capital intensity: Advanced modalities (CT/MRI and related upgrades) require periodic capex and maintenance, impacting free cash flow during investment cycles.

📊 Valuation & Market View

Markets typically value healthcare services with a blended lens:
  • EV/EBITDA as a primary framework for operating performance and reinvestment capacity.
  • P/S considerations can emerge for platform operators when investors focus on recurring referral and interpretation economics, though profitability and reimbursement discipline ultimately dominate.
Key valuation drivers include sustainable volume/utilization, net reimbursement per study (after contractual and billing dynamics), labor productivity, and the credibility of capacity expansion plans that preserve margins. Multiple compression risk tends to follow reimbursement uncertainty or evidence of structural margin erosion.

🔍 Investment Takeaway

RADNET’s long-term thesis rests on an operational platform that links outpatient imaging delivery with interpretation workflow scale. The most durable protections are switching costs created by established referral pathways and integrated reporting workflows, plus credentialing and contracting barriers that slow entry and support retention of payer/provider relationships. Value creation is likely to track utilization discipline, reimbursement optimization, and disciplined capacity expansion rather than financial engineering or short-cycle demand bets.

⚠ AI-generated — informational only. Validate using filings before investing.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"RDNT reported Q1’26 revenue of $575.6M and net income of -$33.5M (EPS -$0.43), with margins sharply pressured (gross margin -3.4%, net margin -5.8%). QoQ, revenue rose from $547.7M (Q4’25) (+5.1%), but profitability deteriorated: net income fell from -$0.6M to -$33.5M (down -5,518%). YoY, revenue increased from $471.4M (Q1’25) (+22.1%), yet net income swung from -$37.9M to -$33.5M (improvement of +11.7%), still remaining deeply loss-making. Over the last four quarters, RDNT’s operating performance has been volatile—several quarters showed positive net income (Q2/Q3’25), while Q4’25 and Q1’26 reverted to losses. Operating cash flow in Q1’26 was strong at $92.3M, even with negative net income, supporting a modest positive free cash flow of $22.3M. However, balance-sheet leverage remains high for a non-bank: total assets were $3.89B and total debt was $1.93B, with net debt increasing to $1.48B as cash declined from $767.2M to $455.3M. Shareholder returns appear mixed: the stock is up +19.5% over 1 year (not above the >20% momentum threshold) and pays no dividend (0% yield)."

Revenue Growth

Positive

Revenue grew +5.1% QoQ ($547.7M to $575.6M) and +22.1% YoY ($471.4M to $575.6M), showing strong top-line momentum.

Profitability

Neutral

Margins contracted materially: gross margin moved from +13.9% (Q4’25) to -3.4% (Q1’26). Net income declined from -$0.6M to -$33.5M QoQ, and EPS was -$0.43 vs -$0.01 in Q4.

Cash Flow Quality

Neutral

Despite negative net income, operating cash flow was $92.3M in Q1’26 and free cash flow was +$22.4M. Still, cash fell QoQ (cash $767.2M to $455.3M) and there were heavy investing/acquisition outflows.

Leverage & Balance Sheet

Caution

Leverage remains elevated: total assets $3.89B with total debt $1.93B and net debt rising to $1.48B. Equity was $1.21B (roughly stable vs Q4’25), but liquidity tightened sharply QoQ.

Shareholder Returns

Neutral

Total return is supported by price appreciation (+19.54% 1y) but is below the >20% momentum emphasis threshold. Dividend yield is 0% and there is no buyback data provided.

Analyst Sentiment & Valuation

Fair

Street consensus price target is ~$92 vs current price $60.39 (implied upside ~52%), but the company is loss-making (negative P/E), increasing valuation uncertainty.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

RadNet delivered record Q1 2026 revenue and adjusted EBITDA despite estimated weather headwinds of $13M revenue and $9M adjusted EBITDA. Reported revenue grew 22.1% and adjusted EBITDA 36.3%, with margin up 115 bps (52 bps normalized vs weather/wildfires). The core operational story is a continued shift to advanced imaging: advanced imaging procedural mix rose 235 bps (29.3% vs 26.9%) alongside same-center advanced imaging volume up 8.2%. Pet/CT and MRI trends were particularly strong, supported by capacity and automation (TechLive remote scanning reducing exam room closure hours). Digital Health accelerated sharply: ARR reached $97M (+95% YoY) with 95% growth and confidence to exceed $140M ARR by year-end; integration of Gleemer is already operational via X-ray AI. Management raised Imaging Center guidance (revenue +$30M, adj EBITDA +$5M, free cash flow +$7M). Key near-term sensitivity is contract-to-revenue timing tied to deployment/go-live execution.

AI IconGrowth Catalysts

  • Advanced imaging mix up: procedural volume 29.3% vs 26.9% prior year (+235 bps), supporting faster throughput/capacity from capital investment
  • TechLive DeepHealth remote scanning reducing exam room closure hours, improving MRI utilization
  • PET/CT demand driven by prostate cancer staging (PSMA) and brain amyloid studies correlated with Alzheimer’s/dementia: +35.2% aggregate and +14.7% same-center
  • Thyroid ultrasound AI automation: slot times from ~30 minutes to ~20 minutes (33% efficiency), with ultrasound same-center +2.1%
  • Thyroid ultrasound AI embedded across nearly 300 sites; X-ray AI live representing >20% of volume in California region

Business Development

  • Imaging Center acquisitions: Radiology Regional purchase of owner of 13 multimodality imaging centers in Southwest Florida (approx. 400 employees, 40+ radiologists)
  • Imaging Center acquisitions: Northwest Radiology acquisition of 6 imaging centers in greater Indianapolis area (founded 1967)
  • Digital Health acquisition: Digital Health acquired Gleemer SAS (France) on March 2; implemented Gleemer clinical X-ray AI across multiple Southern California locations
  • Health system JV partnership: Trinity Health’s Saint Alphonsus Health System (Boise, Idaho) commenced April 30; JV yielding ~$30M annual revenues initially operating 5 centers (including 2 outpatient at Saint Alphonsus medical centers)
  • JV ownership: RadNet purchased 51% interest in the existing partnership entity for ~$17M including the newly commenced Trinity joint venture
  • Digital Health commercial wins: $16M total contract value across 40 customers in Q1; includes UK/EMEA lung AI contracts; $1.5M total contract value North America diagnostics deal

AI IconFinancial Highlights

  • Weather impact acknowledged: estimated $13M revenue and $9M adjusted EBITDA headwind from severe East Coast weather in Jan–Feb
  • Company growth vs prior year: revenue +22.1%; adjusted EBITDA +36.3%; adjusted EBITDA margin +115 bps
  • Normalized for weather/wildfires impacts: adjusted EBITDA margin improved +52 bps
  • Imaging Center segment: adjusted EBITDA margin improved +188 bps vs prior year; normalized improvement still +52 bps
  • Same-center advanced imaging growth: +8.2% same-center advanced imaging procedure volume
  • Digital Health growth: ARR $97M at Q1 end (+95% YoY); Digital Health revenue +51.5% YoY
  • Digital Health external revenue: 64% outside RadNet in Q1 vs 51% prior year; installed base close to ~3,000 global customers
  • Working capital/cash conversion: DSO reduced to a record low 29.5 days

AI IconCapital Funding

  • Cash/liquidity: $455.3M cash at quarter end
  • Revolving credit facility: full availability of $282M revolver
  • Leverage: net debt ~$631M as of March 31, 2026 (at par less cash; includes RadNet’s 49% ownership of New Jersey Imaging Network net debt of $23M, non-borrower/non-guarantor)
  • Net debt to adjusted EBITDA leverage: ~2.0x
  • Cash deployment: leverage increased in Q1 due to acquisitions (Radiology Regional, Northwest Radiology, Gleemer), offset by expected deleveraging supported by strong free cash flow

AI IconStrategy & Ops

  • Operational throughput/capacity: continued deployment of advanced imaging equipment and digital workflow automation to increase utilization and reduce closure hours
  • Automation/workflow platforms: TechLive remote/assistant scanning; AI orchestrator (AI Studio) and AI-curated reporting (Reporting Pro) described as replacing manual case assignments and dictation workflow
  • Embedded AI rollout: thyroid ultrasound AI fully embedded across nearly 300 sites; reporting tools multi-region rollout with deployments in Florida and Texas
  • Regulatory/innovation cadence: innovation engine reached 26 FDA clearances and 22 CE Marks; planning additional 12 FDA clearances and 15 CE Marks by year-end

AI IconMarket Outlook

  • Raised 2026 full-year guidance for Imaging Center business: increased revenue by $30M at both low/high ends; increased adjusted EBITDA by $5M at low/high ends; increased free cash flow by $7M at low/high ends (Digital Health guidance ranges unchanged)
  • Digital Health full-year guidance reaffirmed: total revenue $135M–$145M; adjusted EBITDA $10M–$12M
  • Digital Health ARR target: on track to reach >$140M ARR by year-end
  • Medicare reimbursement 2027: no updates now; CMS physician fee schedule preliminary rates expected June/July; management to comment after Q2 results call in August

AI IconRisks & Headwinds

  • Weather volatility: severe winter weather in Jan–Feb estimated to have reduced revenue by ~$13M and adjusted EBITDA by ~$9M; wildfires previously impacted prior-year comparables
  • Industry mix shift risk: routine imaging growth implied to be lower (management expects low-single-digit population-like growth) while focus shifts to advanced imaging
  • Regulatory timing: revenue timing depends on deployment/go-live schedules after winning signed contracts (ARR vs revenue timing described as install-dependent)

Q&A: Analyst Interest

  • Volume sustainability (normalized for weather): Management attributed advanced imaging strength to technology-driven capacity and same-center performance, citing MRI high single digits (10.1%), CT mid-single digits, and PET/CT growth >14% same-center. They said trends should persist given March strength and digital workflow capacity gains despite weather rebounding.
  • JV/acquisition ramp and upside: Management emphasized funnel visibility as the leading indicator, describing a ~$150M total contract value commercial funnel across diagnostic suite and enterprise operations. They noted ARR-to-revenue timing differences due to deployment capability, focusing on faster installations to realize guidance and post-2026 growth.
  • Routine vs advanced mix dynamics: Management rejected crowding-out for routine, saying the shift is demand/clinical indications enabled by improving equipment and capabilities. They expect routine imaging to grow with population in low single digits while advanced imaging drives disproportionate revenue impact (>60%). They added thyroid AI shortening scan times supporting some routine growth.

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the RDNT Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
© 2026 Stock Market Info — RadNet, Inc. (RDNT) Financial Profile